Moderna Cuts Forecast, Stock Wobbles Despite Beat

Moderna's MRNA quarter was okay on the numbers, but the stock slid because the company pulled back its full-year revenue outlook after delaying some U.K. vaccine shipments into early 2026.

Q2 revenue was $142Million, down 41% from a year ago, with COVID shot sales at $114Million and its RSV vaccine barely registering. That pushed the 2025 revenue range to $1.5Billion$2.2Billion, about $300Million less than before.

The good part is they've been cutting costs aggressively. OpEx is now guided to $5.9Billion$6.1Billion roughly $400Million lighter than prior expectationsand that helped trim the loss to about $800Million. Moderna still has a strong cash cushion: $7.5Billion at the end of June and roughly $6Billion expected at year-end, so the balance sheet isn't stressed.

The delayed shipments rattled sentiment, but the company isn't burning cash. Now it comes down to executionU.K. deliveries must land as rescheduled and new revenue drivers need to show up before investors lose patience.